Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting

Infection Control and Hospital Epidemiology

Volumn 22, Issue 7, 2001, Pages 437-442

  Montecalvo, Marisa A ^a   Jarvis, William R ^b   Uman, Jane ^a   Shay, David K ^b   Petrullo, Coleen ^a   Horowitz, Harold W ^a   Wormser, Gary P ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CALCULATION; COST CONTROL; DISEASE TRANSMISSION; ENTEROCOCCUS; EPIDEMIC; EVALUATION; HEALTH PROGRAM; HOSPITAL COST; HUMAN; INFECTION CONTROL; ONCOLOGY;

EID: 0034820244     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/501931     Document Type: Article

References (11)

1. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993
2. Recommendations for preventing the spread of vancomycin resistance
3. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium
4. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
5. Infection control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting
6. CDC definitions for nosocomial infections, 1988
7. APACHE II: A severity of disease classification system
8. Measuring the costs of nosocomial infections: Methods for estimating economic burden on the hospital
9. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality
10. Natural history of colonization with vancomycin-resistant Enterococcus faecium